HCW Biologics Inc.
HCWB · NASDAQ Global Market · USD
0,954USD
−0,066 (−6,47 %)Stand 9. Nov., 21:00
Vorbörslich0,9540,00 (0,00 %)6:12 ET
Vortag 1,02
Kennzahlen
- Eröffnung
- 1,00
- Vortag
- 1,02
- Tagesspanne
- 0,9501 – 1,055
- 52 Wochen
- 0,9501 – 23,94
- Volumen
- 42.849
- Ø Volumen
- 307.226
- Börsenwert
- 331.650 $
- KGV
- -0,0
- Gewinn je Aktie (TTM)
- -54,17
- Dividendenrendite
- 0,0 %
- Beta
- 2,3
- Nächste Zahlen
- 12. Nov. 2026
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 54.232 | 2,57 Mio. | 2,84 Mio. | 6,72 Mio. | 0 |
| Herstellungskosten | 43.386 | 1,61 Mio. | 2,28 Mio. | 4,14 Mio. | 0 |
| Bruttogewinn | 10.846 | 959.403 | 560.360 | 2,59 Mio. | 0 |
| Forschung und Entwicklung | 5,44 Mio. | 6,39 Mio. | 7,68 Mio. | 9,34 Mio. | 8,17 Mio. |
| Vertrieb und Verwaltung | 7,7 Mio. | 21,95 Mio. | 13,08 Mio. | 7,99 Mio. | 5,3 Mio. |
| Operatives Ergebnis | −11,26 Mio. | −29,48 Mio. | −25,72 Mio. | −15,08 Mio. | −13,37 Mio. |
| EBITDA | −5,67 Mio. | −27,68 Mio. | −23,58 Mio. | −14,06 Mio. | −12,32 Mio. |
| Nettogewinn | −7,96 Mio. | −30,02 Mio. | −24,99 Mio. | −14,9 Mio. | −12,86 Mio. |
| Gewinn je Aktie (verwässert) | -63,78 | -4,62 | -4,20 | -2,52 | -2,16 |
Bewertung
Letzte 12 Monate
- KGV
- -0,0
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- 0,0
- PEG
- 0,0
- Bruttomarge
- 95,9 %
- Operative Marge
- −91,6 %
- Nettomarge
- −73,2 %
- Verschuldungsgrad
- 0,9
- EV/EBITDA
- -1,4
- Eigenkapitalrendite
- −142,2 %
- Kapitalrendite (ROIC)
- −39,3 %
- Free-Cashflow-Rendite
- −3.659,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 20,0 % | 37,4 % | 19,7 % | 38,5 % | 0,0 % |
| Operative Marge | −20.757,6 % | −1.148,5 % | −905,0 % | −224,3 % | 0,0 % |
| Nettomarge | −14.677,1 % | −1.169,7 % | −879,5 % | −221,7 % | 0,0 % |
| KGV | -0,1 | -23,2 | -70,3 | -182,4 | -257,8 |
| Kurs-Umsatz-Verhältnis | 37,5 | 269,6 | 622,0 | 408,2 | 0,0 |
| Kurs-Buchwert-Verhältnis | 0,7 | -102,2 | 131,3 | 73,3 | 64,8 |
| Verschuldungsgrad | 2,5 | -2,0 | 0,5 | 0,2 | 0,0 |
| Liquidität 3. Grades | 0,1 | 0,2 | 0,7 | 11,5 | 17,4 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 6,89 Mio. | 701,09 Mio. | 1,77 Mrd. | 2,73 Mrd. | 3,31 Mrd. |
| EV/EBITDA | -1,2 | -25,3 | -75,1 | -194,1 | -268,5 |
| Eigenkapitalrendite | −287,9 % | 443,5 % | −185,7 % | −39,8 % | −25,1 % |
| Kapitalrendite (ROIC) | −109,7 % | −425,9 % | −130,1 % | −34,4 % | −26,1 % |
| Free-Cashflow-Rendite | −658,1 % | −2,1 % | −1,6 % | −0,8 % | −0,3 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −97,9 % | −9,7 % | −57,7 % | 0,0 % | −100,0 % |
| Bruttogewinn | −98,9 % | +71,2 % | −78,3 % | 0,0 % | −100,0 % |
| Operatives Ergebnis | +61,8 % | −14,6 % | −70,6 % | −12,8 % | −129,5 % |
| Nettogewinn | +73,5 % | −20,1 % | −67,7 % | −15,8 % | −122,5 % |
| Gewinn je Aktie | −1.280,5 % | −10,0 % | −66,7 % | −16,7 % | −125,0 % |
| Freier Cashflow | +7,6 % | +49,5 % | −39,0 % | −87,4 % | −3,8 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 3Kaufen
- 0Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 6,68 Mio. | 33,73 Mio. | 45,65 Mio. |
| Umsatz (Tief – Hoch) | 6,68 Mio. – 6,68 Mio. | 33,73 Mio. – 33,73 Mio. | 45,65 Mio. – 45,65 Mio. |
| Gewinn je Aktie (Ø) | -4,72 | -1,05 | -0,73 |
| Gewinn je Aktie (Tief – Hoch) | -4,72 – -4,72 | -1,05 – -1,05 | -0,73 – -0,73 |
| Analysten | 1 | 1 | 1 |
Letzte Änderungen
- Maxim Group28. Mai 2026Buy
- Maxim Group29. Mai 2025Buy
- EF Hutton19. Apr. 2023Buy
- EF Hutton30. März 2023Buy
- EF Hutton23. März 2023Buy
- JonesTrading8. Nov. 2022Buy
- Maxim Group24. März 2022Buy
- EF Hutton19. Nov. 2021Buy
Quartalszahlen
Nächste Zahlen: 12. Nov. 2026| Aug. 2026 | Mai 2026 | März 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | März 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -1,98 | -2,64 | -5,04 | 9,48 | 10,80 | – | 21,60 | -31,20 |
| Gewinn je Aktie · Tatsächlich | -11,58 | 2,22 | -15,78 | -12,12 | -40,73 | -0,30 | -19,20 | -24,00 |
| Abweichung | −484,85 % | +184,09 % | −213,10 % | −227,85 % | −477,13 % | – | −188,89 % | +23,08 % |
| Umsatz · Tatsächlich | 135.568 | 6,53 Mio. | 27.010 | 85.285 | 1310 | 5065 | 394.804 | 852.850 |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 30. Juni 20261:6
- 11. Apr. 20251:40
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 4,93 %
- Investoren mit 13F-Meldung
- 12
Größte Investoren
- JANE STREET GROUP, LLC2,49 %52.138
- CITADEL ADVISORS LLC0,95 %19.942
- HRT FINANCIAL LP0,65 %13.583
- VANGUARD FIDUCIARY TRUST CO0,31 %6510
- TOWER RESEARCH CAPITAL LLC (TRC)0,20 %4117
- CONNECTIVE CAPITAL MANAGEMENT, LLC0,16 %3338
- VANGUARD CAPITAL MANAGEMENT LLC0,10 %2003
- GOLDEN STATE WEALTH MANAGEMENT, LLC0,08 %1667
Insider-Geschäfte
- Wong Hing C29. Juli 2026 · director, 10 percent owner, officer: Chief Executive OfficerKauf23.210 Aktien · 2,585
- Flowers Lee29. Juli 2026 · officer: SVP of Business DevelopmentKauf7736 Aktien · 2,585
- GARRETT SCOTT T29. Juli 2026 · directorKauf7736 Aktien · 2,585
- Wong Hing C22. Mai 2026 · director, 10 percent owner, officer: Chief Executive OfficerKauf113.879 Aktien · 1,405
- Wong Hing C22. Mai 2026 · director, 10 percent owner, officer: Chief Executive OfficerKauf113.879 Aktien · 1,28
- GARRETT SCOTT T22. Mai 2026 · directorKauf177.936 Aktien · 1,405
- GARRETT SCOTT T22. Mai 2026 · directorKauf177.936 Aktien · 1,28
- Byam Rebecca22. Mai 2026 · officer: Chief Financial OfficerKauf14.235 Aktien · 1,405
Vergleichbare Unternehmen
ACXPAcurx Pharmaceuticals, Inc.1,060,00 %
ADILAdial Pharmaceuticals, Inc.5,05+36,12 %
APREAprea Therapeutics, Inc.0,501−3,21 %
APVOAptevo Therapeutics Inc.1,13−8,87 %
BCDABioCardia, Inc.0,9026+6,19 %
BCLIBrainstorm Cell Therapeutics Inc.0,96+6,67 %
CELZCreative Medical Technology Holdings, Inc.0,6121−1,59 %
INABIN8bio, Inc.0,9401+1,47 %
Über das Unternehmen
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Führung
- Hing C. WongFounder, Chief Executive Officer, Director & Secretary
- Rebecca ByamChief Financial Officer
- Peter RhodeChief Scientific Officer & Vice President of Clinical Operations
- Lee D. FlowersSenior Vice President of Business Development
- Nicole ValdiviesoVice President of Legal Affairs
- CEO
- Hing C. Wong
- Mitarbeitende
- 35
- Hauptsitz
- Miramar, FL, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 20. Juli 2021
- Website
- hcwbiologics.com
Nachrichten
- GlobeNewsWire · 6. Nov., 11:00HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
- GlobeNewsWire · 6. Nov., 9:15HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting
- GlobeNewsWire · 5. Nov., 8:45HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
- Defense World · 12. Okt., 6:00HCW Biologics Inc. (NASDAQ:HCWB) Shares Shorted: Short Interest Up 557.1% in September
- GlobeNewsWire · 9. Okt., 9:00HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
- GlobeNewsWire · 24. Sept., 8:25HCW Biologics Announces Pricing of $1.5 Million Private Placement
- GlobeNewsWire · 8. Sept., 8:50HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
- GlobeNewsWire · 2. Sept., 9:00HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
- GlobeNewsWire · 25. Aug., 9:00HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
- GlobeNewsWire · 14. Aug., 15:15HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.